Long-term follow-data shows Revuforj to be effective in the treatment patients with R/R KMT2Ar acute leukemias.
The disgraced film producer was diagnosed with leukaemia in November. Now his lawyer has confirmed that the 72-year-old was ...
Johnson & Johnson announced new frontline data featuring TECVAYLI from two investigational studies in patients with newly diagnosed ...
A/S announced new results from the Phase 1b/2 EPCORE NHL-2 trial evaluating fixed-duration epcoritamab, a T-cell engaging ...
A subgroup analysis showed that epcoritamab is effective regardless of CAR T–exposure in patients with R/R LBCL.
No Treatment Emergent Adverse Events Leading to Dose Reduction In Non-Hodgkin’s Lymphoma, Cemsidomide Monoth Much of the East Coast was in for a polar reprieve. But that warm-up comes with a price: ...
An investigational therapy for post-traumatic stress disorder (PTSD) improved symptom severity as soon as one month into a 12 ...
Filgotinib, a JAK1 preferential inhibitor, shows promise as an effective and well-tolerated maintenance therapy for Crohn's ...
Scemblix resulted in better outcomes and fewer side effects compared to standard tyrosine kinase inhibitor therapies in ...
An expanded analysis from the phase 3 CEPHEUS trial showed that daratumumab plus VRd improved MRD responses as well as ...
AbbVie (ABBV) announced updated results from the Phase 1b/2 EPCORE NHL-2 trial evaluating fixed-duration investigational ...
Johnson & Johnson (NYSE:JNJ) today announced new frontline data featuring TECVAYLI® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in ...